Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://jamesy906fzn1.tkzblog.com/profile